Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

It took GLP-1 medications like Ozempic just seven years to surpass insulin as the the second most common treatment for type 2 ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Ozempic has recently taken social media by storm, gaining attention for its ability to induce rapid weight loss along with ...

Demand for new weight ... diabetes) is considered a dual GLP-1 and glucose-dependent insulinotropic polypeptide agonist, which may enhance its weight loss benefits. In practice, however, these ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...

Weight-loss jabs will be rolled out across the NHS for the first time in an effort to tackle obesity. Health officials have ...

The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...

The Real Housewives of Salt Lake City cast member detailed the discouraging way people have reacted to her 25-pound weight ...

Ongoing shortages of popular weight loss and diabetes ... are available.” He opined that the medical and legal risk of putting patients on a compounded version of a weight loss medication ...